共 28 条
- [1] SHAFI A, BERRY A J, SUMNALL H, WOOD D M, TRACY D K., New psychoactive substances: a review and updates, Ther Adv Psychopharmacol, 10, pp. 1-21, (2020)
- [2] BATISSE A, EIDEN C, PEYRIERE H, DJEZZAR S., French addictovigilance network. Use of new psychoactive substances to mimic prescription drugs: the trend in France, Neurotoxicology, 79, pp. 20-24, (2020)
- [3] LO FARO A F, DI TRANA A, LA MAIDA N, TAGLIABRACCI A, GIORGETTI R, BUSARDO F P., Biomedical analysis of new psychoactive substances (NPS) of natural origin, J Pharm Biomed Anal, 179, (2020)
- [4] KURCEVIC E, LINES R., New psychoactive substances in Eurasia: a qualitative study of people who use drugs and harm reduction services in six countries, Harm Reduct J, 17, 1, (2020)
- [5] PATOCKA J, ZHAO B, WU W, KLIMOVA B, VALIS M, NEPOVIMOVA E, KUCA K., Flakka: new dangerous synthetic cathinone on the drug scene[J], Int J Mol Sci, 21, 21, pp. 8-185, (2020)
- [6] GRAZIANO S, ANZILLOTTI L, MANNOCCHI G, PICHINI S, BUSARDO F P., Screening methods for rapid determination of new psychoactive substances (NPS) in conventional and non-conventional biological matrices, J Pharm Biomed Anal, 163, pp. 170-179, (2019)
- [7] VARI M R, MANNOCCHI G, TITTARELLI R, CAMPANOZZI L L, NITTARI G, FEOLA A, UMANI RONCHI F, RICCI G., New psychoactive substances: evolution in the exchange of information and innovative legal responses in the European Union[J], Int J Environ Res Public Health, 17, 22, pp. 8-704, (2020)
- [8] FATTORE L, WEINSTEIN A M., Editorial: novel psychoactive drugs, Front Psychiatry, 10, (2019)
- [9] GRIGG J, MANNING V, ARUNOGIRI S, LUBMAN D I., Synthetic cannabinoid use disorder: an update for general psychiatrists, Australas Psychiatry, 27, 3, pp. 279-283, (2019)
- [10] RINALDI R, BERSANI G, MARINELLI E, ZAAMI S., The rise of new psychoactive substances and psychiatric implications: a wide-ranging, multifaceted challenge that needs far-reaching common legislative strategies, Hum Psychopharmacol, 35, 3, (2020)